Skip to content

Effect and mechanism of artificial liver therapy on Intestinal Microecology in patients with chronic hepatitis B-related liver failure

Effect and mechanism of artificial liver therapy on Intestinal Microecology in patients with chronic hepatitis B-related liver failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044980
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-03-25
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B-related liver failure

Interventions

Acute-on-chronic liver failure group:None
Healthy conrol group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Acute-on-chronic liver failure group: (1) On the basis of chronic hepatitis B, patients with acute jaundice intensification and coagulation dysfunction as manifestations of liver failure syndrome caused by various triggers and patients with hepatic encephalopathy, ascites, electrolyte imbalance, infection, hepatorenal syndrome or with complications such as hepatopulmonary syndrome and failure of extrahepatic organs can be combined with. (2) Patients whose jaundice deepened rapidly, and the serum TBil increased >= 10 x ULN or increased >= 17.1 µmol/L daily or with hemorrhage, PTA= 1.5). 2. Inclusion criteria of healthy control group (HC): (1) Healthy men who have undergone physical examination and voluntary recruitment at West China Hospital. (2) The medical history investigation showed that he was healthy, had no history of liver and gastrointestinal diseases, and had no previous hypertension, diabetes and other systemic diseases. (3) No history of surgery within 6 months and blood viral hepatitis markers were negative, and blood liver function and renal function tests showed no abnormalities.

Exclusion criteria

Exclusion criteria: 1. With autoimmune hepatitis, alcoholic hepatitis, drug-induced hepatitis and hepatitis caused by unknown causes; 2. With hepatocellular carcinoma and patients with severe primary diseases of heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract or psychosis.

Design outcomes

Primary

MeasureTime frame
intestinal flora;

Countries

China

Contacts

Public ContactZhou Shaoqun

West China Hospital of Sichuan University

781217505@qq.com+86 15882477233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026